Marco Cioce1, Rossana Moroni2, Maria Carola Gifuni3, Stefano Botti4, Laura Orlando5, Sonia Soave6, Ivana Serra7, Maurizio Zega8, Giampaolo Gargiulo9. 1. Fondazione Policlinico Gemelli IRCCS, Roma. UOC Ematologia e Trapianto di Cellule Staminali Emopoietiche. Cell +393472284176. 2. Fondazione Policlinico Gemelli IRCCS, Roma. Biostatistico presso Direzione Scientifica. 3. Fondazione Policlinico Gemelli IRCC, Roma. UOC Ematologia e Trapianto di Cellule Staminali Emopoietiche. 4. Azienda USL-IRCCS, Reggio Emilia. UOC Ematologia. 5. IEO Istituto Europeo di Oncologia, Milano. Area Assistenziale Omogenea Medica. 6. Fondazione Policlinico Tor Vergata, Roma. UOC Ematologia. 7. Fondazione Policlinico Gemelli IRCCS, Roma. 8. Fondazione Policlinico Gemelli IRCCS, Roma. Direttore SITRA. 9. AOU Federico II, Napoli. UOC Ematologia e Trapianto di cellule Staminali Emopoie- tiche.
Abstract
INTRODUCTION: Haematopoietic Stem Cell Transplantation ( HSCT) has become the standard of care for some haematological diseases that do not respond to traditional treatments: pre-transplant therapy still causes high mortality and morbidity today. Due to the high risk, patient care requires careful evalua- tion and often complex, intensive and non-risk free interventions; the NANDA-I classification provides a way to classify and standardise areas of nursing interest. A previous consensus among experts had iden- tified 61 diagnoses, according to the classification NANDA-I 2018-2020, relevant in onco-haematolo- gical field. OBJECTIVE: The aim of the study was to identify which of the 61 diagnoses were relevant for patients undergoing HSCT. METHOD: A Delphi study was conducted in two rounds; a structured questionnaire on a 4 point Likert scale was used to build consensus, involving 57 experienced nurse enrolled in Italian GITMO Centres. RESULTS: The present study has identified 34 relevant NANDA-I diagnoses in patients undergoing HSCT; it also defined 11 as important diagnoses having obtained absolute consensus. DISCUSSION: Use the NANDA-I diagnoses to know, from a panel of experts, the most important and relevant health problems associated with the toxicity of pre- HCSE treatment, it can direct assistance and resources towards expercied and known outcomes so as to be able to intervene effectively with performances aimed at reducing risks and specific complications.
INTRODUCTION: Haematopoietic Stem Cell Transplantation ( HSCT) has become the standard of care for some haematological diseases that do not respond to traditional treatments: pre-transplant therapy still causes high mortality and morbidity today. Due to the high risk, patient care requires careful evalua- tion and often complex, intensive and non-risk free interventions; the NANDA-I classification provides a way to classify and standardise areas of nursing interest. A previous consensus among experts had iden- tified 61 diagnoses, according to the classification NANDA-I 2018-2020, relevant in onco-haematolo- gical field. OBJECTIVE: The aim of the study was to identify which of the 61 diagnoses were relevant for patients undergoing HSCT. METHOD: A Delphi study was conducted in two rounds; a structured questionnaire on a 4 point Likert scale was used to build consensus, involving 57 experienced nurse enrolled in Italian GITMO Centres. RESULTS: The present study has identified 34 relevant NANDA-I diagnoses in patients undergoing HSCT; it also defined 11 as important diagnoses having obtained absolute consensus. DISCUSSION: Use the NANDA-I diagnoses to know, from a panel of experts, the most important and relevant health problems associated with the toxicity of pre- HCSE treatment, it can direct assistance and resources towards expercied and known outcomes so as to be able to intervene effectively with performances aimed at reducing risks and specific complications.